Again, no COVID-19 benefit found from hydroxychloroquine, azithromycinA retrospective study of COVID-19 patients in New York City hospitals found that treatment with the antimalaria drug hydroxychloroquine, the antibiotic azithromycin, or both was not significantly associated with differences in in-hospital mortality compared with patients who received neither drug.
But cardiac arrest was more frequent in patients treated with both drugs, according to the findings published yesterday in JAMA.Of 1,438 COVID-19 patients treated at 25 New York City hospitals from Mar 15 through Mar 28, 735 (51.1%) received hydroxychloroquine and azithromycin, 271 (18.8%) received hydroxychloroquine alone, 211 (14.7%) received azithromycin alone, and 221